Phase II Trial of BK-UM against HB-EGF in combination with Gemcitabine in Patients with advanced or recurrent ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2015
At a glance
- Drugs CRM 197 (Primary) ; Gemcitabine (Primary)
- Indications Ovarian cancer
- Focus Biomarker; Therapeutic Use
- 03 Aug 2015 Status changed from active, no longer recruiting to discontinued as per University Hospital Medical Information Network - Japan record.
- 15 May 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 05 Mar 2013 New trial record